SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K was filed by Synaptogenix, Inc. (SNPX) on April 28, 2023, reporting an event that occurred on April 24, 2023. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. Its common stock trades on The Nasdaq Capital Market under the symbol "SNPX."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
On April 24, 2023, the Company received written notice from Nasdaq stating that its common stock failed to maintain a minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). This notice has no immediate effect on the listing or trading of the stock.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has a 180-day grace period, ending October 23, 2023, to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price remains at or above $1.00 for 10 consecutive business days during the grace period.
- Secondary Compliance Option: If the price requirement is not met by the deadline, the Company may be eligible for additional time if it meets the market value of publicly held shares requirement and other initial listing standards. This may require effecting a reverse stock split.
- Risk: Failure to cure the deficiency could result in delisting from The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of SNPX to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding the intent to effect a reverse stock split if the price does not recover naturally.
- Review the Company's market value of publicly held shares to determine eligibility for the second compliance period.
- Check for any subsequent 8-K filings regarding the status of the delisting notice or approval of a reverse stock split.